Latest arGEN-X Stories

BREDA, The Netherlands and GHENT, Belgium, April 24, 2013 /PRNewswire/ -- First program based on proprietary ABDEG(TM) technology to promote degradation and clearance of disease-causing autoantibodies arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed its second product candidate this year into formal preclinical development. Complementing its...

BREDA, The Netherlands and GHENT, Belgium, March 25, 2013 /PRNewswire/ -- ARGX-112 targets IL22R1, a novel target involved in chronic skin inflammation arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development. ARGX-112 is a novel, fully human...

BREDA, the Netherlands, January 7, 2013 /PRNewswire/ -- New Discovery Program Initiated Within 12 Months Of Collaboration Start arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody products, is broadening its therapeutic antibody collaboration with Shire. Initiated in March 2012, the existing alliance is focused on arGEN-X using its SIMPLE Antibody(TM) discovery platform to create novel...

BREDA, the Netherlands, and GHENT, Belgium, January 7, 2013 /PRNewswire/ -- arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody(TM) program to enter the clinic in just three years from initiation of discovery. ARGX-110 is a first-in-class CD70-targeting monoclonal...

BREDA, the Netherlands and GHENT, Belgium, October 25, 2012 /PRNewswire/ -- arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody(TM) platform, has strengthened its supervisory board with the appointment of Dr. David L. Lacey. Dr. Lacey is a former Senior Vice President and Head of Discovery Research at Amgen with over 30 years of basic and clinical research experience. He played...

ROTTERDAM, the Netherlands and GHENT, Belgium, March 19, 2012 /PRNewswire/ -- ADDS A SECOND PROPRIETARY TECHNOLOGY TO LEVERAGE THE POWER OF THE SIMPLE ANTIBODY(TM) PLATFORM arGEN-X announces today the launch of NHance(TM), its latest cutting-edge technology enabling the creation of truly differentiated human antibody therapeutics. NHance(TM) technology significantly prolongs the circulation time of therapeutic antibodies in the human body by engineering of the...

ROTTERDAM, the Netherlands and GHENT, Belgium, March 19, 2012 /PRNewswire/ -- arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody(TM) platform, announces today that it has strengthened its management team with two key hires. Alain Thibault, MD joins the Company as Chief Medical Officer, while Jacobus (Koos) Rasser, PhD, JD will serve as IP Counsel. Dr. Alain Thibault has gained...

ROTTERDAM, The Netherlands, September 7, 2011 /PRNewswire/ -- SIMPLE Antibody(TM) platform continues to demonstrate clear advantages in therapeutic antibody discovery arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody(TM) platform, will provide an update on this year's significant corporate progress during a presentation by its CEO Tim Van Hauwermeiren...

ROTTERDAM, The Netherlands, July 8, 2010 /PRNewswire/ -- - Novel Platform Set to Transform Human Therapeutic Antibody Discovery & Development arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody(TM) platform, announces that it has been granted the first patent covering the platform. The patent GB2461546B, has been granted by the UK Patent and Trademark Office (UKPTO). The...

ROTTERDAM, The Netherlands, March 1, 2010 /PRNewswire/ -- - SIMPLE Antibody(TM) Platform Delivers Unprecedented Choice of Ultra-Potent Functional Antibody Leads Against Challenging Soluble and Cell Surface Targets. - ARGX-109, a Fully Human mAb Targeting Autoimmune, Inflammation and Oncology Indications, Enters Preclinical Development in Less Than 12 Months From Start of Discovery. arGEN-X, a biopharmaceutical company focused on the discovery...